First in China! Qingfeng Pharmaceutical's Brivaracetam Tablets Approved for Marketing

On June 28, the Brivaracetam tablets (trade name: Qingruitan®) developed by Qingfeng Pharmaceutical Group were officially approved for marketing by the National Medical Products Administration. The approval of Brivaracetam tablets fills a domestic gap, provides another powerful tool for the treatment of epilepsy in my country, and brings new options to epilepsy patients and their families.

Brivaracetam tablets are indicated for monotherapy and add-on treatment of partial-onset seizures in patients with epilepsy aged 4 years and above.

Epilepsy is a common paroxysmal neurological disease, listed by the World Health Organization as one of the five most intractable diseases of the nervous system. It is also the second most intractable neurological disease after cerebrovascular disease.

Brivaracetam is a new third-generation anti-epileptic drug that can bind to the central synaptic vesicle protein (SV2A) with high affinity and can more easily pass the blood-brain barrier. A large number of clinical studies have shown that Brivaracetam has few adverse reactions, especially in terms of irritability and aggressiveness, the incidence and severity of adverse reactions are low; Brivaracetam can also improve the cognitive function of epilepsy patients, improve patients' attention and executive function, improve patients' reaction time, and improve patients' quality of life. Brivaracetam is suitable for a wide range of people, is easy to administer, does not require titration, and the initial dose is the therapeutic dose. It can take effect quickly and maintain a high clinical efficacy in long-term treatment; it has high tolerance and still shows good clinical effects after long-term use.

Central nervous system (CNS) is one of Qingfeng Pharmaceutical’s key focus area. In recent years, Qingfeng Pharmaceutical has made full deployment in this field. Brivaracetam tablets are another new member of Qingfeng Pharmaceutical's anti-epileptic drug family after the launch of lacosamide tablets, lacosamide injection, lacosamide oral solution, sodium valproate injection concentrated solution, and perampanel tablets. The launch of this product further enriches Qingfeng Pharmaceutical's central nervous system product line and provides new treatment options and more comprehensive solutions for epilepsy patients.

Currently, Qingfeng Pharmaceutical is developing nearly 20 types of anti-epileptic drugs, forming a product matrix with multiple categories and dosage forms including oral solid preparations, oral liquid preparations, injections, etc., and is leading the country in this segment.

In the future, Qingfeng Pharmaceutical will continue to uphold the corporate mission of "Providing sustainable and high-quality service for human health", focus on unmet clinical needs in key areas, rely on the company's R&D and technical capabilities, continuously optimize and integrate the company's existing resources, and strive to become a leader in special segments such as the central nervous system.